Last reviewed · How we verify
Allogenic MSC
At a glance
| Generic name | Allogenic MSC |
|---|---|
| Also known as | Biochymal |
| Sponsor | Taiwan Bio Therapeutics Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments (PHASE2)
- Comparing Clinical Outcomes of the One-step Cartilage Transplantation in Cartilage Defects of the Knee With Conservative Treatment (PHASE3)
- Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy (PHASE2)
- Double-blind, Randomized, Controlled Clinical Trial to Assess Efficacy of MSC in Patients With COVID-19 ARDS (PHASE2)
- MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma (PHASE1)
- Allogeneic Human Mesenchymal Stem Cell Infusion for Frailty Patient (NA)
- Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury (PHASE1, PHASE2)
- Pilot Study of Radiation-Induced Xerostomia Treatment With Allogeneic Mesenchymal Stromal Stem Cells (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Allogenic MSC CI brief — competitive landscape report
- Allogenic MSC updates RSS · CI watch RSS
- Taiwan Bio Therapeutics Inc. portfolio CI